Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: A microRNA molecular modeling extension for prediction of colorectal cancer treatment

Fig. 3

Sensitivity scores of CRC cancer cell lines. a: the plot visualizes how CRC cancer cell lines respond to the treatment of dasatinib, erlotinib, and everolimus. b: the plot quantitatively displays how CRC cancer cell lines respond to the treatment of gefitinib, imatinib and lapatinib. c: the plot quantitatively shows how CRC cancer cell lines respond to the treatment of nilotinib, sorafenib, sunitinib and temsirolimus. All data are attached in the Additional file 2 (Exp: experimentally based sensitivity score; Sim: model-based sensitivity score). d: R2 measure between responses (GI-50) of CRC cell lines and predicted sensitivity scores to treatments of everolimus and temsirolimus

Back to article page